Reported 8 days ago
In a recent CNBC segment, Jim Cramer advised investors to maintain their positions in Eli Lilly (LLY), highlighting its potential in treating various health conditions and its strong market position with GLP-1 drugs. Despite a revenue miss attributed to supply chain issues, Cramer remains optimistic about the company's future, urging investors to adapt to the new economic landscape shaped by President Trump's trade policies.
Source: YAHOO